In a post-hoc analysis of this group, Praluent was associated with a lower risk of death from any cause by 29%. The results give a clear advantage to Sanofi and Regeneron in the duel with Repatha ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

Amgen has just won its patent case in the Federal Court in Delaware, a jury deciding that Sanofi and Regeneron's Praluent (alirocumab) infringed on two patents on Amgen's competing drug Repatha ...